课题基金 / 基金详情

PET IMAGING AND SEROTONIN LIGANDS IN EATING DISORDERS

PET IMAGING AND SEROTONIN LIGANDS IN EATING DISORDERS
饮食失调中的宠物成像和血清素配体
批准号:
6499214
负责人:
WALTER H KAYE
金额:
$11.72万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-02-15 至 2006-01-31

项目摘要

项目成果

WALTER H KAYE的其他基金

相关文献

中文摘要
翻译
描述:几行间接证据表明,大脑中的5-羟色胺 神经性厌食症(AN)和神经性暴食症(BN)的女性会发生改变 当他们生病时和康复后。从理论上讲,与性状相关的增加 5-羟色胺的神经传递可能导致脆弱性(限制进食, 痴迷于秩序和完美主义、避免伤害和负面影响) 这有助于发展AN和BN。反过来,营养不良可能会降低5-羟色胺 神经元活动,进而减少烦躁不安的情感状态, 尤其是在一个。 新技术提供了直接表征动态的可能性 5-羟色胺受体功能与人类行为的关系在短期内 (第1至第4年),资助的研究将调查5组18至45岁的女性 年龄:1)患病的AN和BN妇女;2)康复的AN和BN妇女(大于1 月经正常,不暴饮暴食,体重健康稳定); 3)健康对照妇女。在AIM 1,150 PET成像和18-F-Altanserin将 评估突触后5-羟色胺-2A型受体结合。初步数据支持 康复的AN和BN妇女的可能性将减少 眼眶前额叶5-羟色胺-2A型受体的发现与增加的证据相关 胞外5-羟色胺。增加2A发现和减少细胞外5-羟色胺将 多见于AN和BN受试者。在AIM 2 150 PET成像和11-C-WAY100635 研究将评估5-HT-1a受体的结合情况。小鼠基因敲除的研究 支持这样一种假设,即突触前中缝自身受体的功能障碍 可能导致5-羟色胺活性增加和行为症状。因此,1a 结合可能不会随着病情的变化而改变。目标3将测试核心 AN或BN症状或冲动控制与5-羟色胺神经元活动有关。 为了全面了解5-羟色胺的14个或更多受体和其他成分 神经通路可能需要多个配体。长期(第3至第5年) 候选人寻求利用这一K05来开发多中心协作 1)利用PET成像和放射性配基综合表征的研究 5-羟色胺及其相关系统在AN和BN中的作用和2)建立的啮齿动物模型 5-羟色胺对行为的影响。此外,这个K05奖项将支持培训 候选人,他将在这些方面培训成熟的和年轻的调查人员 新技术。了解生物脆弱性,例如 5-羟色胺紊乱,发生在AN和BN可能有助于开发新的 对这些通常是慢性和致命疾病的治疗干预以及 阐明了5-羟色胺的神经传递与行为的关系。
英文摘要
DESCRIPTION: Several lines of indirect evidence suggest that brain serotonin alterations occur in women with anorexia nervosa (AN) and bulimia nervosa (BN) when they are ill and after recovery. In theory, a trait-related increase of 5-HT neurotransmission may contribute to vulnerabilities (restricted feeding, obsessions with order and perfectionism, harm avoidance and negative affect) that contribute to developing AN and BN. In turn, malnutrition may reduce 5-HT neuronal activity, which in turn reduces dysphoric affective states, particularly in AN. New technologies offer the potential of direct characterization of dynamic relations between 5-HT receptor function and human behavior. In the short term (years 1 to 4), funded studies will investigate five groups of women 18 to 45 years old: 1) ill AN and BN women; 2) recovered AN and BN women (greater than 1 year normal menses, no binging and purging, and healthy and stable weight); and 3) healthy control women. In Aim 1, 150 PET imaging and 18-F-altanserin will assess 5-HT-2A postsynaptic receptor binding. Preliminary data support the possibility that recovered AN and BN women will have a reduction of orbitofrontal 5-HT-2A receptor finding associated with evidence of increased extracellular 5-HT. Increased 2A finding and decreased extracellular 5-HT will occur in ill AN and BN subjects. In Aim 2 150 PET imaging and 11-C-WAY100635 studies will assess 5-HT-1A receptor binding. Knockout gene studies in mice support the hypothesis that a malfunction of pre-synaptic raphe autoreceptors could contribute to increased 5-HT activity and behavioral symptoms. Thus, 1A binding may not change with state of the illness. Aim 3 will test whether core AN or BN symptoms or impulse control are related to 5-HT neuronal activity. To fully characterize the 14 or more receptors and other components of the 5-HT neuronal pathways may require multiple ligands. In the long term (years 3 to 5) the candidate seeks to use this K05 to develop a multicenter collaborative study to 1) use PET imaging and radioligands to comprehensively characterize 5-HT and related systems in AN and BN and 2) develop rodent models relating 5-HT to behavior. In addition, this K05 award will support training the candidate, who in turn will train established and young investigators in these new technologies. Understanding whether biologic vulnerabilities, such as a 5-HT disturbance, occurs in AN and BN may contribute to developing a new treatment interventions for these often chronic and deadly disorders as well as shed light on the relation of 5-HT neurotransmission and behavior.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Family Therapy in the Treatment of Adolescent Anorexia Nervosa
Family Therapy and Fluoxetine in the treatment of Adolescent Anorexia Nervosa
Family Therapy and Fluoxetine in the treatment of Adolescent Anorexia Nervosa
Family Therapy and Fluoxetine in the Treatment of Adolescents